Inve India ▾

Indegene share price & results

Indegene· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Tech-enabled commercialization, medical & regulatory services partner to global biopharma firms.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue341 ₹ crore+33.2% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin18.0 %+4.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit60.0 ₹ crore+33.3% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity14.46 %−6.2 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin17.29 %+2.8 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)30.37 %+14.0 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

6 of 9 judged targets kept · 8 open · verdicts reflect calls analysed to Q1 FY27.

Indegene management guidance track record on Inve: 17 targets tracked across analysed earnings calls (6 achieved, 3 missed, 8 open).

TargetOriginal wordingSaidLatest callVerdict
EBITDA MarginFairly stable
Call transcript, Q4 FY25 · 29 Apr 2025		Q4 FY25Q1 FY27:The promise pertained to FY26 and was achieved. No further updates applicable.
Call transcript, Q1 FY27 · 31 Jul 2026		Achieved
New Deal Contribution$2 million to $4 million ACV each for five key deals
Call transcript, Q3 FY25 · 31 Jan 2025		Q3 FY25Q1 FY27:No mention of these specific deals from FY25. The promise remains unaddressed and is now six quarters old.
Call transcript, Q1 FY27 · 31 Jul 2026		Ghosted
EPS Accretion (BioPharm)Accretive beyond 5-6 quarters
Call transcript, Q1 FY26 · 6 Oct 2025		Q1 FY26Q1 FY27:The target period of 5-6 quarters from Q1 FY26 is approaching (ends Q2-Q3 FY27). No specific update on EPS accretion was provided, but overall business integration is proceeding.
Call transcript, Q1 FY27 · 31 Jul 2026		On Track

Source: Inve Guidance Tracker for Indegene · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

3 of Indegene's 17 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 14 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹601.75 +5.22% · +₹29.85

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance +11.4% 1Y

₹450₹500₹550₹600Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 31 Oct 2025Q3 FY26 — 30 Jan 2026Q4 FY26 — 30 Apr 2026Q1 FY27 — 31 Jul 2026

1Y: ₹540.15 on 24 Oct 2025 → ₹601.75. High ₹613.3 (28 Sept 2026), low ₹423.5 (23 Mar 2026).

Previous close
₹571.9
Market cap
₹14.5k Cr
52-week range
₹423.5 – ₹613.3
One year
+10.75%
Price to earnings (TTM to Jun 2026)
34.85×
Return on equity (TTM to Jun 2026)
14.46%

Overview

Symbol
NSE:INDGN
Exchange
NSE
Currency
INR

What Indegene does

Based on the company's own presentations, annual report and earnings calls.

Indegene provides outsourced, technology- and AI-enabled services to biopharmaceutical and life sciences companies across the drug commercialization lifecycle, from clinical trial support and regulatory/pharmacovigilance operations to sales & marketing, medical communications and patient engagement. It earns revenue under two delivery models -- enterprise-wide, technology-enabled Centers of Excellence staffed with domain experts and GenAI agents delivering multi-year global engagements, and dedicated omnichannel activation teams -- billed either on a resource-utilization/fixed-price basis or on outcome-based pricing for select engagements. Services are delivered through proprietary AI/GenAI platforms including the NEXT suite (covering MLR review automation, adverse event management, content collaboration, forecasting and channel optimization) and Invisage(TM), its omnichannel sales and marketing platform. The company has grown its client base and technology capability partly through acquisitions.

Segments

  • Enterprise Commercial Solutions
  • Enterprise Medical Solutions
  • Omnichannel Activation Solutions
  • Others
Active client relationships
91 (FY26), up from 44 in FY21
Clients contributing $1M+ in annual revenue
53 (FY26)
Top global biopharma companies served
Partner to 20 of the Top 20 and 80 of the Top 100 global life sciences companies
Global offices
19
Employee footprint
5,000+ employees globally -- 4,153 in India, 588 in North America, 185 in Europe, 79 in other regions (as of 31 Mar 2025)
Delivery employees with healthcare qualifications
23.8% hold healthcare-related degrees (MD, MBBS, PhD, BDS, MPharm, BPharm)
Founded 1998Headquarters Bengaluru, Karnataka, India Company website

How the price took the results

close before → close after

Q1 FY27
+0.1%
31 Jul
Q4 FY26
+0.9%
30 Apr
Q3 FY26
+2.8%
30 Jan
Q2 FY26
−2.3%
31 Oct

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Indegene

Free account: one company. Everything above stays public.

Write why you follow Indegene and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Indegene

Guides on how to read this kind of business and the numbers that matter.